Additionally, MOC31PE has a competitive edge over earlier anti-EpCAM antibody-based treatments due to its “simpler” mode of action, requiring just binding to EpCAM-expressing cancer cells before directly promoting cancer cell death through toxin release inside the target cells [61,62]. This evidence concerns the gene EPCAM and cancer.